CD37 CAR T cells have been preclinically tested for efficacy in B cell lymphomas which exhibited robust effector functions, Th1-type cytokines expression, and tumor clearance in the MCL-PDX model. The gene discussed is CD37; the disease is B-cell non-Hodgkin lymphoma.